Since our analysis goes back to 2003, when BRCA1/2 genetic testing was not a routine test for ovarian cancer patients in Greece, data regarding BRCA1/2 mutation status are limited and therefore not included in the multivariate analysis. This evidence concerns the gene BRCA1 and ovarian cancer.